Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Heather Gottlieb

Urogynecology and Reconstructive Pelvic Surgery Newtown, PA Doctor of Osteopathy

NPI 1164402806 CMS profile 325029

2189 Second Street Pike, Ste 200, Newtown, PA 18940

Open in the dashboard

General payments

$48,028

302 records reported · program years 2019–2025

Research payments

$355

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Heather Gottlieb of Newtown, PA is reported in the CMS Open Payments database as having received $48,028 across 302 general payments and $355 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,056 27
2024 General $10,148 75
2023 General $13,511 51
2022 General $7,191 44
2022 Research $355 1
2021 General $6,486 39
2020 General $4,793 20
2019 General $843 46

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Heather Gottlieb
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Heather Gottlieb were reported at $5,056. Among 149 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $779 and the middle half received between $301 and $2,705.

Show as a table
Year Heather Gottlieb Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $843 $799 $319–$2,013 $163
2020 $4,793 $384 $158–$1,360 $114
2021 $6,486 $641 $247–$2,515 $132
2022 $7,191 $843 $347–$2,794 $149
2023 $13,511 $819 $308–$2,302 $160
2024 $10,148 $882 $306–$2,459 $164
2025 $5,056 $779 $301–$2,705 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $39,611 83 payments
  2. Medtronic USA, Inc. $4,897 30 payments
  3. Astellas Pharma US Inc $582 36 payments
  4. AbbVie, Inc. $537 24 payments
  5. Sumitomo Pharma America, Inc. $482 35 payments
  6. 180 Medical, Inc. $192 8 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $183 8 payments
  8. Allergan Inc. $178 9 payments
  9. Coloplast Corp $159 9 payments
  10. Mission Pharmacal Company $127 8 payments
  11. Other $1,080 52 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $40,000 23 payments
  2. Food and Beverage $6,720 271 payments
  3. Travel and Lodging $975 2 payments
  4. Education $333 6 payments
Products named General payments · program years 2019–2025
  1. INTERSTIM Sacral Nerve Stimulation $39,456 82 payments
  2. INTERSTIM Sacral Nerve Stimulation $4,897 30 payments
  3. GEMTESA $597 40 payments
  4. BOTOX Urology $267 8 payments
  5. BOTOX Botox Therapeutic $245 12 payments
  6. MYRBETRIQ $231 30 payments
  7. Xofigo $183 8 payments
  8. Nubeqa $183 8 payments
  9. ALTAVIVA $155 1 payment
  10. GENTLECATH $127 4 payments
  11. Other $1,621 85 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $355 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

2,724

Median for Urology: 1,053

Drug cost

$688,944

Median for Urology: $101,464

Branded share of claims

43.8%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 287 $260,772
Gemtesa Vibegron Brand 312 $242,276
Elmiron Pentosan Polysulfate Sodium Brand 68 $112,690
Estradiol Generic 396 $25,385
Methenamine Hippurate Generic 208 $18,464
Mirabegron Er Mirabegron Brand 12 $8,323
Amitriptyline Hcl Generic 296 $3,782
Hydroxyzine Hcl Generic 145 $2,637
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 294 $2,187
Solifenacin Succinate Generic 54 $1,737

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$161,263

Of which drugs: $6,216

Medicare patients

474

Average age 73

Services billed

13,529

443 women, 31 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 60%
Osteoporosis 36%
Depression 32%
Diabetes 20%
Ischemic heart disease 19%
Chronic kidney disease 18%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 75 10,600 $3,108

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $303
$303 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $271
$271 312 —
PYLARIFY
  • Progenics Pharmaceuticals, Inc. $22
$22 — —
LUPRON DEPOT
  • AbbVie, Inc. $19
$19 — —
JELMYTO
  • UROGEN PHARMA, INC. $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

303 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record